SCHEMBL30729630

SCHEMBL30729630

CC(C)(C)OC(=O)N1CCN2c3ncc(C(F)(F)F)cc3NC(=O)[C@@H]2C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TIPARP Q7Z3E1 7/20 0.53
CBLB Q13191 1/20 0.53
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC8 Q9BY41 1/20 0.41
MDM2 Q00987 1/20 0.40
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
SCN9A Q15858 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
SYK P43405 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
STS P08842 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26959306 1.00 TIPARP (0.53) TIPARPCBLBMEN1KMT2AMAPT
SCHEMBL26959030 1.00 TIPARP (0.53) TIPARPCBLBMEN1KMT2AMAPT
SCHEMBL29274212 0.88 KDM4E (0.43) TIPARPCBLBMEN1KMT2AMAPT
SCHEMBL23102322 0.86 KDM4E (0.43) TIPARPCBLBMEN1KMT2AMAPT
SCHEMBL23102324 0.86 KDM4E (0.43) TIPARPCBLBMEN1KMT2AMAPT
SCHEMBL29841734 0.86 TIPARP (0.53) TIPARPCBLBMEN1KMT2AMAPT
SCHEMBL26915094 0.86 TIPARP (0.53) TIPARPCBLBMEN1KMT2AMAPT
SCHEMBL29841803 0.86 TIPARP (0.53) TIPARPCBLBMEN1KMT2AMAPT
SCHEMBL26914999 0.86 TIPARP (0.53) TIPARPCBLBMEN1KMT2AMAPT
SCHEMBL29841783 0.86 TIPARP (0.43) TIPARPCBLBMEN1KMT2AHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166664-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-05-23 US disclosed
EP-4289845-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2023-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166664-A1 TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 TIPARP 23/4885CBLB 4600/4885MEN1 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.